Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
Reports First Quarter 2012 Results
5/15/2012 9:36:19 AM
CLEVELAND, May 14, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) today announced its financial results for the first quarter of 2012.
Announces Meeting With
to Discuss Advancing Clinical Development of MultiStem(R) for the Prevention of GvHD
Release: Publication in Cell Transplantation Indicates That MultiStem(R) Could be Used in Treatment of Orphan Neurological Disorders
Savient Pharmaceuticals, Inc.
(SVNT)'s Loss Widens on Higher Krystexxa Costs
to Host First Quarter 2012 Financial Results Call
Boehringer Ingelheim Corporation
's 2011 Profit Jumps 66 Percent
Receives U.S. Patent Covering the Suppression of Graft-versus-Host Disease Associated With Hematopoietic Stem Cell Transplantation With Adult Stem Cells
(NVS) Quarterly Profit Drops as Diovan, OTC Sales Slump
Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
(AMGN) Posts Strong Drug Sales, Beats Estimates
comments powered by Disqus.
comments powered by
Biotech/Pharma - Earnings